JP MORGAN/CALL/BECTON DICKINSON AND CO./265/0.1/17.01.25 Share Price

Warrant

DE000JL1KNV1

Market Closed - Börse Stuttgart 08:26:53 07/06/2024 BST
1.49 EUR +11.19% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./265/0.1/17.01.25
Current month+47.52%
1 month-8.02%
Date Price Change
07/06/24 1.49 +11.19%
06/06/24 1.34 -10.67%
05/06/24 1.5 +2.74%
04/06/24 1.46 +18.70%
03/06/24 1.23 +21.78%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 08:26 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL1KNV
ISINDE000JL1KNV1
Date issued 05/04/2023
Strike 265 $
Maturity 17/01/2025 (224 Days)
Parity 10 : 1
Emission price 2.68
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 5.92
Lowest since issue 0.85
Spread 0.15
Spread %8.98%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
240.6 USD
Average target price
278.7 USD
Spread / Average Target
+15.81%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW